Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Global Phase 3 Masupirdine Study in Alzheimer’s Disease Agitation; Trial Continues Unchanged 04/06/2026 / Operations & Projects / Clinical Development Update Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Global Phase 3 Masupirdine Study in Alzheimer’s Disease Agitation; Trial Continues Unchanged Read Post »
